How to treat stage D heart failure?: When to implant left ventricular assist devices in the era of continuous flow pumps?

Circulation Journal

Volumn 75, Issue 9, 2011, Pages 2038-2045

  Kinugawa, Koichiro ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Heart failure; Prognosis; Ventricular assist devices

Indexed keywords

BUCINDOLOL; CARVEDILOL; DIGITALIS; DIURETIC AGENT; ENALAPRIL; PLACEBO; SPIRONOLACTONE;

CARDIAC RESYNCHRONIZATION THERAPY; CLINICAL TRIAL (TOPIC); DEFIBRILLATOR; DISEASE CLASSIFICATION; DISEASE RESISTANCE; DISEASE SEVERITY; DRUG EFFICACY; HEART ASSIST DEVICE; HEART FAILURE; HEART TRANSPLANTATION; HUMAN; IMPLANTATION; MORTALITY; POSTOPERATIVE PERIOD; PREDICTION; PROGNOSIS; REVIEW; RISK FACTOR; STAGE D HEART FAILURE;

AMERICAN HEART ASSOCIATION; CLINICAL TRIALS AS TOPIC; HEART FAILURE; HEART VENTRICLES; HEART-ASSIST DEVICES; HUMANS; PRACTICE GUIDELINES AS TOPIC; UNITED STATES;

EID: 80052249350     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-11-0621     Document Type: Review

References (39)

1. Writing Committee Members, Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, et al. 2009 focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults: A report of the American College of Cardiology Foundation/American Heart Association Task Force On Practice Guidelines: Developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009; 119: e391-e479.
2. Effects of enalapril on mortality in severe congestive heart failure. N Engl J Med 1987; 316: 1429-1435.
3. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999; 341: 709-717.
4. Beta-Blocker Evaluation of Survival Trial Investigators. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med 2001; 344: 1659-1667.
5. Packer M, Coats AJS, Fowler MB, Katus HA, Krum H, Mohacsi P, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001; 344: 1651-1658.
6. Lindenfeld J, Feldman AM, Saxon L, Boehmer J, Carson P, Ghali JK, et al. Effects of cardiac resynchronization therapy with or without a defibrillator on survival and hospitalizations in patients with New York Heart Association class IV heart failure. Circulation 2007; 115: 204-212.
7. Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, De Marco T, et al; Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Investigators. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004; 350: 2140-2150.
8. Slaughter MS, Rogers JG, Milano CA, Russell SD, Conte JV, Feldman D, et al. Advanced heart failure treated with continuous-flow left ventricular assist device. N Engl J Med 2009; 361: 2241-2251.
9. Rose EA, Gelijns AC, Moskowitz AJ, Heitjan DF, Stevenson LW, Dembitsky W, et al. Long-term use of a left ventricular assist device for end-stage heart failure. N Engl J Med 2001; 345: 1435-1443.
10. Stevenson LW, Miller LW, Desvigne-Nickens P, Ascheim DD, Parides MK, Renlund DG, et al. Left ventricular assist device as destination for patients undergoing intravenous inotropic therapy: A subset analysis from REMATCH (randomized evaluation of mechanical assistance in treatment of chronic heart failure). Circulation 2004; 110: 975-981.
11. Aaronson KD, Schwartz JS, Chen TM, Wong KL, Goin JE, Mancini DM. Development and prospective validation of a clinical index to predict survival in ambulatory patients referred for cardiac transplant evaluation. Circulation 1997; 95: 2660-2667.
12. Levy WC, Mozaffarian D, Linker DT, Sutradhar SC, Anker SD, Cropp AB, et al. The Seattle Heart Failure Model: Prediction of survival in heart failure. Circulation 2006; 113: 1424-1433.
13. Stevenson LW, Pagani FD, Young JB, Jessup M, Miller L, Kormos RL, et al. INTERMACS profiles of advanced heart failure: The current picture. J Heart Lung Transplant 2009; 28: 535-541.
14. Baldwin JT, Mann DL. NHLBI's program for VAD therapy for moderately advanced heart failure: The REVIVE-IT pilot trial. J Card Fail 2010; 16: 855-858.
15. Kirklin JK, Naftel DC, Kormos RL, Stevenson LW, Pagani FD, Miller MA, et al. Second INTERMACS annual report: More than 1,000 primary left ventricular assist device implants. J Heart Lung Transplant 2010; 29: 1-10.
16. Shiga T, Kinugawa K, Hatano M, Yao A, Nishimura T, Endo M, et al. Age and preoperative total bilirubin level can stratify prognosis after extracorporeal pulsatile left ventricular assist device implantation. Circ J 2010; 75: 121-128.
17. Saito S, Matsumiya G, Sakaguchi T, Miyagawa S, Yoshikawa Y, Yamauchi T, et al. Risk factor analysis of long-term support with left ventricular assist system. Circ J 2010; 74: 715-722.
18. Matthews JC, Koelling TM, Pagani FD, Aaronson KD. The right ventricular failure risk score: A pre-operative tool for assessing the risk of right ventricular failure in left ventricular assist device candidates. J Am Coll Cardiol 2008; 51: 2163-2172.
19. Ochiai Y, McCarthy PM, Smedira NG, Banbury MK, Navia JL, Feng J, et al. Predictors of severe right ventricular failure after implantable left ventricular assist device insertion: Analysis of 245 patients. Circulation 2002; 106: I-198-I-202.
20. Strueber M, Meyer AL, Malehsa D, Haverich A. Successful use of the HeartWare HVAD rotary blood pump for biventricular support. J Thorac Cardiovasc Surg 2010; 140: 936-937.
21. Saito S, Sakaguchi T, Miyagawa S, Yoshikawa Y, Yamauchi T, Ueno T, et al. Biventricular support using implantable continuous-flow ventricular assist devices. J Heart Lung Transplant 2011; 30: 475-478.
22. Saito S, Sakaguchi T, Sawa Y. Clinical report of long-term support with dual Jarvik 2000 biventricular assist device. J Heart Lung Transplant 2011; 30: 845-847.
23. Farrar DJ. Preoperative predictors of survival in patients with Thoratec ventricular assist devices as a bridge to heart transplantation: Thoratec ventricular assist device principal investigators. J Heart Lung Transplant 1994; 13: 93-100.
24. Korfer R, El-Banayosy A, Arusoglu L, Minami K, Korner MM, Kizner L, et al. Single-center experience with the Thoratec ventricular assist device. J Thorac Cardiovasc Surg 2000; 119: 596-600.
25. McBride LR, Naunheim KS, Fiore AC, Moroney DA, Swartz MT. Clinical experience with 111 Thoratec ventricular assist devices. Ann Thorac Surg 1999; 67: 1233-1238.
26. Frazier OH, Rose EA, Macmanus Q, Burton NA, Lefrak EA, Poirier VL, et al. Multicenter clinical evaluation of the HeartMate 1000 IP left ventricular assist device. Ann Thorac Surg 1992; 53: 1080-1090.
27. Frazier OH, Rose EA, McCarthy P, Burton NA, Tector A, Levin H, et al. Improved mortality and rehabilitation of transplant candidates treated with a long-term implantable left ventricular assist system. Ann Surg 1995; 222: 327-336.
28. Frazier OH, Rose EA, Oz MC, Dembitsky W, McCarthy P, Radovancevic B, et al. Multicenter clinical evaluation of the Heart-Mate vented electric left ventricular assist system in patients awaiting heart transplantation. J Thorac Cardiovasc Surg 2001; 122: 1186-1195.
29. Nojiri C. Implantable left ventricular assist system. Circ J 2009; 73: A-48-A-54.
30. Miller LW, Pagani FD, Russell SD, John R, Boyle AJ, Aaronson KD, et al. Use of a continuous-flow device in patients awaiting heart transplantation. N Engl J Med 2007; 357: 885-896.
31. Pagani FD, Miller LW, Russell SD, Aaronson KD, John R, Boyle AJ, et al. Extended mechanical circulatory support with a continuousflow rotary left ventricular assist device. J Am Coll Cardiol 2009; 54: 312-321.
32. Kirklin JK, Naftel DC, Kormos RL, Stevenson LW, Pagani FD, Miller MA, et al. Third INTERMACS annual report: The evolution of destination therapy in the united states. J Heart Lung Transplant 2011; 30: 115-123.
33. Yamazaki K, Kihara S, Akimoto T, Tagusari O, Kawai A, Umezu M, et al. EVAHEART: An implantable centrifugal blood pump for longterm circulatory support. Jpn J Thorac Cardiovasc Surg 2002; 50: 461-465.
34. Morshuis M, El-Banayosy A, Arusoglu L, Koerfer R, Hetzer R, Wieselthaler G, et al. European experience of DuraHeart magnetically levitated centrifugal left ventricular assist system. Eur J Cardiothorac Surg 2009; 35: 1020-1027.
35. Cowger J, Pagani FD, Haft JW, Romano MA, Aaronson KD, Kolias TJ. The development of aortic insufficiency in LVAD supported patients. Circ Heart Fail 2010; 3: 668-674.
36. Hatano M, Kinugawa K, Shiga T, Kato N, Endo M, Hisagi M, et al. Less frequent opening of the aortic valve and a continuous flow pump are risk factors for postoperative onset of aortic insufficiency in patients with a left ventricular assist device. Circ J 2011; 75: 1147-1155.
37. John R, Mantz K, Eckman P, Rose A, May-Newman K. Aortic valve pathophysiology during left ventricular assist device support. J Heart Lung Transplant 2010; 29: 1321-1329.
38. Uriel N, Pak SW, Jorde UP, Jude B, Susen S, Vincentelli A, et al. Acquired von Willebrand syndrome after continuous-flow mechanical device support contributes to a high prevalence of bleeding during long-term support and at the time of transplantation. J Am Coll Cardiol 2010; 56: 1207-1213.
39. Demirozu ZT, Radovancevic R, Hochman LF, Gregoric ID, Letsou GV, Kar B, et al. Arteriovenous malformation and gastrointestinal bleeding in patients with the HeartMate II left ventricular assist device. J Heart Lung Transplant 2011; 30: 849-853.